Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
31 Jan 2020
31 Jan 2020
Historique:
entrez:
2
2
2020
pubmed:
2
2
2020
medline:
2
2
2020
Statut:
epublish
Résumé
After publication of the original article [1], we were notified that an author's surname has been erroneously spelled. Elisabetta Maragoni's family name should be replaced with Marangoni.
Identifiants
pubmed: 32005287
doi: 10.1186/s13058-020-1254-5
pii: 10.1186/s13058-020-1254-5
pmc: PMC6993431
doi:
Types de publication
Published Erratum
Langues
eng
Sous-ensembles de citation
IM
Pagination
14Commentaires et corrections
Type : ErratumFor
Références
Breast Cancer Res. 2019 Dec 4;21(1):135
pubmed: 31801615